India’s decision to resume export of Covid-19 vaccines welcomed

At the Quad summit,  India conveyed its decision to resume vaccine exports from October and this was welcomed by all members of the informal group. Taking forward the Quad vaccine initiative, it was noted that Biological E, a Hyderabad-based company, would be producing one million doses of the vaccine by October 2021. India would be financing 50 percent of the first consignment of this vaccine.

Overall with investments from Quad countries, Biological E will produce at least one billion safe and effective COVID-19 vaccines by the end of 2022.

As per the joint statement after the summit, Japan will help regional partners purchase vaccines through $3.3 billion of COVID-19 Crisis Response Emergency Support Loan. Australia will deliver $212 million in grant aid to purchase vaccines for Southeast Asia and the Pacific. Australia will also allocate $219 million to support last-mile vaccine rollouts.

Significantly, through the COVAX initiative, India, Japan, Australia and the US have pledged to donate more than 1.2 billion doses globally of safe and effective Covid-19 vaccines. Till now, the Quad members have delivered nearly 79 million, safe, effective and quality-assured vaccine doses to countries in the Indo-Pacific region.

The Quad leaders also decided to strengthen their Science and Technology (S&T) cooperation in the areas of clinical trials and genomic surveillance so that they can accelerate their efforts to end this pandemic and build better health security.

Image courtesy of (Photo: PIB)

Share this post